S J Kim 1, N Ikeda, E Shiba, Y Takamura, S Noguchi. 1. Department of Surgical Oncology, Osaka University Medical School, 2-2-E-10 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Abstract
BACKGROUND: Although there have been many reports on the immunocytochemical detection of bone marrow micrometastases in breast cancer patients, peripheral blood micrometastases (PBM) have rarely been studied by immunocytochemistry (ICC). METHODS: PBM in operable and metastatic breast cancer patients were studied using immunomagnetic separation of tumor cells followed by immunocytochemistry (IMS-ICC). RESULTS: PBM were not detected in any peripheral blood samples from 21 healthy women, six patients with benign disease, or in a 21 patients with primary operable breast cancer, of which there were 7 stage I (n=7), 9 stage II, 2 stage III, and 3 inflammatory tumors. On the other hand, PBM were detected in 8 of 29 patients with metastatic breast cancers (27.6%). The number of tumor cells per patient varied from 2 to 90 cancer cells (median: 8 cells). Positivity of PBM was not significantly associated with the first site of recurrence, number of involved organs, tumor marker status, performance status, or disease-free interval, but it was significantly (p<0.01) associated with progesterone receptor negativity. CONCLUSION: PBM are very rare in primary operable breast cancer patients but can be observed in a considerable number of metastatic breast cancer patients. The clinical significance of PBM still remains to be established.
BACKGROUND: Although there have been many reports on the immunocytochemical detection of bone marrow micrometastases in breast cancerpatients, peripheral blood micrometastases (PBM) have rarely been studied by immunocytochemistry (ICC). METHODS:PBM in operable and metastatic breast cancerpatients were studied using immunomagnetic separation of tumor cells followed by immunocytochemistry (IMS-ICC). RESULTS:PBM were not detected in any peripheral blood samples from 21 healthy women, six patients with benign disease, or in a 21 patients with primary operable breast cancer, of which there were 7 stage I (n=7), 9 stage II, 2 stage III, and 3 inflammatory tumors. On the other hand, PBM were detected in 8 of 29 patients with metastatic breast cancers (27.6%). The number of tumor cells per patient varied from 2 to 90 cancer cells (median: 8 cells). Positivity of PBM was not significantly associated with the first site of recurrence, number of involved organs, tumor marker status, performance status, or disease-free interval, but it was significantly (p<0.01) associated with progesterone receptor negativity. CONCLUSION:PBM are very rare in primary operable breast cancerpatients but can be observed in a considerable number of metastatic breast cancerpatients. The clinical significance of PBM still remains to be established.
Authors: Robert T Krivacic; Andras Ladanyi; Douglas N Curry; H B Hsieh; Peter Kuhn; Danielle E Bergsrud; Jane F Kepros; Todd Barbera; Michael Y Ho; Lan Bo Chen; Richard A Lerner; Richard H Bruce Journal: Proc Natl Acad Sci U S A Date: 2004-07-12 Impact factor: 11.205
Authors: B A S Jaeger; J Jueckstock; U Andergassen; J Salmen; F Schochter; V Fink; M Alunni-Fabbroni; M Rezai; Th Beck; M W Beckmann; K Friese; T W P Friedl; W Janni; B Rack Journal: Biomed Res Int Date: 2014-04-08 Impact factor: 3.411